Biolife Solutions INC Form 4 insider transactions

Sean Werner, Chief Technology Officer of BioLife Solutions Inc., reports acquiring 22,919 shares of common stock on March 18, 2025, as part of his 2025 compensation.

Roderick de Greef, President and CEO of BioLife Solutions, reports acquiring 112,835 shares of common stock on March 18, 2025, according to a Form 4 filing with the SEC.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold a portion of her common stock holdings under a pre-arranged Rule 10b5-1 trading plan.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 1,577 shares of common stock on March 11, 2025, to cover tax obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold shares of common stock under pre-arranged 10b5-1 trading plans.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 1,597 shares of common stock on March 11, 2025, to cover tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 1,331 shares of common stock on March 11, 2025, at a price of $25 per share to cover tax obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 4,151 shares of common stock on March 11, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sean Werner, Chief Technology Officer of BioLife Solutions, sold shares of common stock on March 3rd and 4th, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 324 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 425 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 660 shares of common stock on March 3, 2025, at a price of $25.46 per share to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 284 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 424 shares of common stock on March 3, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 92 shares of common stock on February 12, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 159 shares of common stock on February 12, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions Inc., sold 78 shares of common stock on February 12, 2025, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 102 shares of common stock on February 12, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 53 shares of common stock on February 12, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions, sold 240 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Biolife Solutions' Executive Vice President and Chief Scientific Officer, Aby J. Mathew, sold 404 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 343 shares of common stock at $27.02 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

BioLife Solutions CEO, Roderick de Greef, sold 46,896 shares of common stock at $23.43 per share under a pre-arranged 10b5-1 trading plan.

Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 328 shares of common stock on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 987 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold a total of 20,800 shares of common stock on December 16 and 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 581 shares of common stock at $27.2 per share on November 26, 2024, under a pre-arranged 10b5-1 trading plan.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, sold 523 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 349 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.

BioLife Solutions' Chief Human Resources Officer, Sarah Aebersold, sold 216 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.